Microglia,originating from primitive macrophages in the yolk sac,serves as both immune system defenders and regulators of homeostasis.These cells exhibit two primary polarization states:conventionally activated(M1)and...Microglia,originating from primitive macrophages in the yolk sac,serves as both immune system defenders and regulators of homeostasis.These cells exhibit two primary polarization states:conventionally activated(M1)and alternatively activated(M2).The polarization of microglia plays a crucial role in influencing inflammatory disorders,metabolic imbalances,and neural degeneration.This process is implicated in various aspects of ocular diseases,especially age-related macular degeneration(AMD),including inflammation,oxidative stress and pathological angiogenesis.The distinct functional phenotypes of microglia impact disease progression and prognosis.Thus,regulating the polarization or functional phenotype of microglia at different stages of AMD holds promise for personalized therapeutic approaches.This comprehensive review outlines the involvement of microglia polarization in both physiological and pathological conditions,emphasizing its relevance in AMD.The discussion underscores the potential of polarization as a foundation for personalized treatment strategies for AMD.展开更多
Objective：To evaluate the probability and efficacy of endostatin-vascular endothelial growth inhibitor （VEGI） recombinant adenoviruses combined with dexamethasone on suppressing heterolamellar corneal transplantati...Objective：To evaluate the probability and efficacy of endostatin-vascular endothelial growth inhibitor （VEGI） recombinant adenoviruses combined with dexamethasone on suppressing heterolamellar corneal transplantation rejection. Methods： Heterolamellar corneal transplantation models were established in 64 New Zealand rabbits, which were randomized into 4 groups of 16 rabbits each. After the transplantation, all the 64 right eyes were injected subconjunctively with 0.2 ml saline （saline group）, 0. 1 ml AdCA13-hENDO-VEGI151 plus 0. 1 ml saline （AdCA13-hENDO-VEGI151 group）, 0. 1 ml Dexamethasone （DXM） plus 0.1 ml saline （DXM group）, 0. 1 ml AdCA13-hENDO-VEGI151 plus 0. 1 ml DXM （AdCA13-hENDO-VEGI151 combined with DXM group） with one time each 3 days for 10 times. Graft survival and ocular surface were observed for 6 weeks. The fusion protein expression was detected by immunohistochemistry 6 weeks after transplantation. Results： Both the CNV index, rejection index and the xenograft rejection rate in the AdCA13-hENDO-VEGI151 combined with DXM group were statistically lower than those in other groups. AdCA13-hENDO-VEGI151 combined with DXM group： 1. 375 0±0. 500 0, 2. 750 0 ±1. 843 9 and 6.25% respectively 6 week after keratoplasty; Saline group： 3. 437 5±0. 512 3, 8. 812 5± 1. 108 7, 100. 00%; AdCA13-hENDO-VEGI151 group： 2. 312 5±0. 478 7, 5. 625 0±0. 957 4, 62.50%; DXM group： 3. 000 0±0. 816 5, 5. 562 5±1. 315 0, 56.25% （P〈0.01）. Immunohistochemical staining showed the fusion protein expressed mainly in corneal epithelium. Conclusion： The fusion protein expressed by the recombinant adenovirus has significant effect on inhibiting neovascularization after heterolamellar corneal transplantation. The topical application of AdCA13-hENDO-VEGI151 combined with DXM suppressed effectively the postoperative xenograft rejection rate of heterolamellar corneal transplantation.展开更多
Objectives To assess the clinical efficacy,safety,and feasibility of autologous transplantation of mobilized peripheral blood mononuclear cells(PBMNCs)for patients with peripheral arterial occlusive disease(PAOD)of th...Objectives To assess the clinical efficacy,safety,and feasibility of autologous transplantation of mobilized peripheral blood mononuclear cells(PBMNCs)for patients with peripheral arterial occlusive disease(PAOD)of the lower extremity.Methods A total of 152 patients with PAOD of the lower extremity were enrolled into this non-controlled observational study from November 2003 to March 2006.All patients received subcutaneous injections of recombinant human granulocyte colony-stimulating factor(G-CSF,450-600μg/day)for 5 days in order to mobilize stem/progenitor cells;their PBMNCs were collected and transplanted by multiple intramuscular injections into ischemic limbs.Patients were followed up for at least 12 weeks.Results At 12 weeks,primary manifestations,including lower limb pain and coldness,were significantly improved in 137(90.1%)of the patients;limb ulcers improved or healed in 46(86.8%)of the 53 patients,while 25 of the 48(47.9%)patients with limb gangrene remained steady or improved.Ankle-brachial index(ABI)improved in 33(22%)of the cases,and TcPO_(2) increased in 45(30%)of the cases.Angiography before treatment,and at 12 weeks after treatment,was performed in 10 of the patients and showed formation of new collateral vessels.No severe adverse effects or complications specifically related to cell transplantation were observed.Conclusion Autologous transplantation of G-CSF-mobilized PBMNCs might be a safe and effective treatment for lower limb ischemic disorder.展开更多
文摘Microglia,originating from primitive macrophages in the yolk sac,serves as both immune system defenders and regulators of homeostasis.These cells exhibit two primary polarization states:conventionally activated(M1)and alternatively activated(M2).The polarization of microglia plays a crucial role in influencing inflammatory disorders,metabolic imbalances,and neural degeneration.This process is implicated in various aspects of ocular diseases,especially age-related macular degeneration(AMD),including inflammation,oxidative stress and pathological angiogenesis.The distinct functional phenotypes of microglia impact disease progression and prognosis.Thus,regulating the polarization or functional phenotype of microglia at different stages of AMD holds promise for personalized therapeutic approaches.This comprehensive review outlines the involvement of microglia polarization in both physiological and pathological conditions,emphasizing its relevance in AMD.The discussion underscores the potential of polarization as a foundation for personalized treatment strategies for AMD.
基金Support by the National Natural Science Foundation of China (No. 30271391, 30170891) the 973 Program (the Development Program of National Key Basic Research Projects (2003CB514129)
文摘Objective：To evaluate the probability and efficacy of endostatin-vascular endothelial growth inhibitor （VEGI） recombinant adenoviruses combined with dexamethasone on suppressing heterolamellar corneal transplantation rejection. Methods： Heterolamellar corneal transplantation models were established in 64 New Zealand rabbits, which were randomized into 4 groups of 16 rabbits each. After the transplantation, all the 64 right eyes were injected subconjunctively with 0.2 ml saline （saline group）, 0. 1 ml AdCA13-hENDO-VEGI151 plus 0. 1 ml saline （AdCA13-hENDO-VEGI151 group）, 0. 1 ml Dexamethasone （DXM） plus 0.1 ml saline （DXM group）, 0. 1 ml AdCA13-hENDO-VEGI151 plus 0. 1 ml DXM （AdCA13-hENDO-VEGI151 combined with DXM group） with one time each 3 days for 10 times. Graft survival and ocular surface were observed for 6 weeks. The fusion protein expression was detected by immunohistochemistry 6 weeks after transplantation. Results： Both the CNV index, rejection index and the xenograft rejection rate in the AdCA13-hENDO-VEGI151 combined with DXM group were statistically lower than those in other groups. AdCA13-hENDO-VEGI151 combined with DXM group： 1. 375 0±0. 500 0, 2. 750 0 ±1. 843 9 and 6.25% respectively 6 week after keratoplasty; Saline group： 3. 437 5±0. 512 3, 8. 812 5± 1. 108 7, 100. 00%; AdCA13-hENDO-VEGI151 group： 2. 312 5±0. 478 7, 5. 625 0±0. 957 4, 62.50%; DXM group： 3. 000 0±0. 816 5, 5. 562 5±1. 315 0, 56.25% （P〈0.01）. Immunohistochemical staining showed the fusion protein expressed mainly in corneal epithelium. Conclusion： The fusion protein expressed by the recombinant adenovirus has significant effect on inhibiting neovascularization after heterolamellar corneal transplantation. The topical application of AdCA13-hENDO-VEGI151 combined with DXM suppressed effectively the postoperative xenograft rejection rate of heterolamellar corneal transplantation.
文摘Objectives To assess the clinical efficacy,safety,and feasibility of autologous transplantation of mobilized peripheral blood mononuclear cells(PBMNCs)for patients with peripheral arterial occlusive disease(PAOD)of the lower extremity.Methods A total of 152 patients with PAOD of the lower extremity were enrolled into this non-controlled observational study from November 2003 to March 2006.All patients received subcutaneous injections of recombinant human granulocyte colony-stimulating factor(G-CSF,450-600μg/day)for 5 days in order to mobilize stem/progenitor cells;their PBMNCs were collected and transplanted by multiple intramuscular injections into ischemic limbs.Patients were followed up for at least 12 weeks.Results At 12 weeks,primary manifestations,including lower limb pain and coldness,were significantly improved in 137(90.1%)of the patients;limb ulcers improved or healed in 46(86.8%)of the 53 patients,while 25 of the 48(47.9%)patients with limb gangrene remained steady or improved.Ankle-brachial index(ABI)improved in 33(22%)of the cases,and TcPO_(2) increased in 45(30%)of the cases.Angiography before treatment,and at 12 weeks after treatment,was performed in 10 of the patients and showed formation of new collateral vessels.No severe adverse effects or complications specifically related to cell transplantation were observed.Conclusion Autologous transplantation of G-CSF-mobilized PBMNCs might be a safe and effective treatment for lower limb ischemic disorder.
